Medical Prognosis Institute A/S
http://http://www.medical-prognosis.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From Medical Prognosis Institute A/S
Allarity Hopes To Breathe New Life Into Ixempra In Breast Cancer
The US precision medicine company hopes its drug response predictor technology will enhance responses to the chemotherapy Ixempra on the basis of promising data from a handful of breast cancer patients in a Phase II trial, marking a positive turn in its journey to date.
Silicon Valley Bank Advisor Predicts 2022 Will Be Year For Healthtech, Massive Consolidation
SVB health care advisor Jonathan Norris anticipates more consolidation in devices ahead with many mid-cap public companies looking to acquire innovative technologies to grow, and pushing the “big guys to have to figure out how to move faster.”
Deal Watch: Pfizer, BioAtla Team Up To Develop Targeted Antibody Oncologics
ViroMed looks to bluebird to take its humanized antibody to the next steps of development in immuno-oncology. Takeda gets option for Cour's nanoparticle technology in Celiac disease, as well as up to three other indications.
Deals Shaping The Medical Industry, July 2015
Derived from Strategic Transactions, Informa’s premium source for tracking life sciences deal activity, the Dealmaking column is a survey of recent health care transactions listed by relevant industry segment – In Vitro Diagnostics, Medical Devices, and Pharmaceuticals – and then categorized by type – Acquisition, Alliance, or Financing. This month’s column covers deals announced in June 2015.
Company Information
- Industry
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Pharmacogenetics-Pharmacogenomics
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice